110 related articles for article (PubMed ID: 21463907)
1. MR-based analysis of regional cardiac function in relation to cellular integrity in Fabry disease.
Koeppe S; Neubauer H; Breunig F; Weidemann F; Wanner C; Sandstede J; Machann W; Hahn D; Köstler H; Beer M
Int J Cardiol; 2012 Sep; 160(1):53-8. PubMed ID: 21463907
[TBL] [Abstract][Full Text] [Related]
2. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment.
Niemann M; Herrmann S; Hu K; Breunig F; Strotmann J; Beer M; Machann W; Voelker W; Ertl G; Wanner C; Weidemann F
JACC Cardiovasc Imaging; 2011 Jun; 4(6):592-601. PubMed ID: 21679893
[TBL] [Abstract][Full Text] [Related]
3. Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease.
Krämer J; Niemann M; Liu D; Hu K; Machann W; Beer M; Wanner C; Ertl G; Weidemann F
Eur Heart J; 2013 Jun; 34(21):1587-96. PubMed ID: 23520186
[TBL] [Abstract][Full Text] [Related]
4. Myocardial Storage, Inflammation, and Cardiac Phenotype in Fabry Disease After One Year of Enzyme Replacement Therapy.
Nordin S; Kozor R; Vijapurapu R; Augusto JB; Knott KD; Captur G; Treibel TA; Ramaswami U; Tchan M; Geberhiwot T; Steeds RP; Hughes DA; Moon JC
Circ Cardiovasc Imaging; 2019 Dec; 12(12):e009430. PubMed ID: 31826677
[TBL] [Abstract][Full Text] [Related]
5. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease.
Weidemann F; Breunig F; Beer M; Sandstede J; Störk S; Voelker W; Ertl G; Knoll A; Wanner C; Strotmann JM
Eur Heart J; 2005 Jun; 26(12):1221-7. PubMed ID: 15728649
[TBL] [Abstract][Full Text] [Related]
6. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study.
Imbriaco M; Pisani A; Spinelli L; Cuocolo A; Messalli G; Capuano E; Marmo M; Liuzzi R; Visciano B; Cianciaruso B; Salvatore M
Heart; 2009 Jul; 95(13):1103-7. PubMed ID: 19372091
[TBL] [Abstract][Full Text] [Related]
7. The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy.
Niemann M; Breunig F; Beer M; Herrmann S; Strotmann J; Hu K; Emmert A; Voelker W; Ertl G; Wanner C; Weidemann F
Heart; 2010 Dec; 96(23):1915-9. PubMed ID: 20965976
[TBL] [Abstract][Full Text] [Related]
8. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study.
Weidemann F; Breunig F; Beer M; Sandstede J; Turschner O; Voelker W; Ertl G; Knoll A; Wanner C; Strotmann JM
Circulation; 2003 Sep; 108(11):1299-301. PubMed ID: 12952834
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease.
Zamorano J; Serra V; Pérez de Isla L; Feltes G; Calli A; Barbado FJ; Torras J; Hernandez S; Herrera J; Herrero JA; Pintos G
Eur J Echocardiogr; 2011 Sep; 12(9):671-7. PubMed ID: 21810826
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.
Weidemann F; Niemann M; Breunig F; Herrmann S; Beer M; Störk S; Voelker W; Ertl G; Wanner C; Strotmann J
Circulation; 2009 Feb; 119(4):524-9. PubMed ID: 19153271
[TBL] [Abstract][Full Text] [Related]
11. Enzyme replacement therapy improves cardiac features and severity of Fabry disease.
Motwani M; Banypersad S; Woolfson P; Waldek S
Mol Genet Metab; 2012 Sep; 107(1-2):197-202. PubMed ID: 22704481
[TBL] [Abstract][Full Text] [Related]
12. Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease.
Collin C; Briet M; Tran TC; Beaussier H; Benistan K; Bensalah M; Mousseaux E; Froissart M; Bozec E; Laurent S; Boutouyrie P; Germain DP
Eur J Prev Cardiol; 2012 Feb; 19(1):43-54. PubMed ID: 21450622
[TBL] [Abstract][Full Text] [Related]
13. Fabry disease.
Yuasa T; Takenaka T; Higuchi K; Uchiyama N; Horizoe Y; Cyaen H; Mizukami N; Takasaki K; Kisanuki A; Miyata M; Ohishi M
J Echocardiogr; 2017 Dec; 15(4):151-157. PubMed ID: 28674962
[TBL] [Abstract][Full Text] [Related]
14. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.
Kampmann C; Linhart A; Devereux RB; Schiffmann R
Clin Ther; 2009 Sep; 31(9):1966-76. PubMed ID: 19843486
[TBL] [Abstract][Full Text] [Related]
15. Normal left-atrial structure and function despite concentric left-ventricular remodelling in a cohort of patients with Anderson-Fabry disease.
Putko BN; Yogasundaram H; Chow K; Pagano J; Khan A; Paterson DI; Thompson RB; Oudit GY
Eur Heart J Cardiovasc Imaging; 2015 Oct; 16(10):1129-36. PubMed ID: 25750198
[TBL] [Abstract][Full Text] [Related]
16. Tei index in fabry disease.
Niemann M; Breunig F; Beer M; Hu K; Liu D; Emmert A; Herrmann S; Ertl G; Wanner C; Takenaka T; Tei C; Weidemann F
J Am Soc Echocardiogr; 2011 Sep; 24(9):1026-32. PubMed ID: 21719255
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease.
Talbot AS; Lewis NT; Nicholls KM
Heart; 2015 Feb; 101(4):287-93. PubMed ID: 25381325
[TBL] [Abstract][Full Text] [Related]
18. Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease.
Krämer J; Niemann M; Störk S; Frantz S; Beer M; Ertl G; Wanner C; Weidemann F
Am J Cardiol; 2014 Sep; 114(6):895-900. PubMed ID: 25073565
[TBL] [Abstract][Full Text] [Related]
19. High-Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease.
Seydelmann N; Liu D; Krämer J; Drechsler C; Hu K; Nordbeck P; Schneider A; Störk S; Bijnens B; Ertl G; Wanner C; Weidemann F
J Am Heart Assoc; 2016 May; 5(6):. PubMed ID: 27247331
[TBL] [Abstract][Full Text] [Related]
20. Myocardial lipid content in Fabry disease: a combined
Petritsch B; Köstler H; Weng AM; Horn M; Gassenmaier T; Kunz AS; Weidemann F; Wanner C; Bley TA; Beer M
BMC Cardiovasc Disord; 2016 Oct; 16(1):205. PubMed ID: 27793097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
